Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Clinical trial NCT00388063 · COMPLETED
Trial details
- NCT number
- NCT00388063
- Sponsor
- Callisto Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-10-01
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.